Transdel Pharmaceuticals Provides Update on Timing of Results for Pha...(opportunities for potential products in ...),Health

Date:6/15/2009

opportunities for potential products in pain management and other therapeutic areas utilizing the Transdel(TM) platform technology and we are exploring potential partnerships for these identified products. Some of these identified co-development areas include hormone based products, antiemetic and dermatological products. We are also looking to out-license our Transdel(TM) drug delivery technology for the development and commercialization of additional innovative drug products.

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company's innovative-patented Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. The Company is actively investigating other product candidates for transdermal delivery using the Transdel(TM) platform technology and is also actively pursuing partnerships with other groups or companies to expand its product portfolio for pharmaceutical and cosmetic/cosmeceutical products. The Company recently announced that they entered into a license agreement with JH Direct, LLC for the exclusive worldwide rights to Transdel's anti-cellulite cosmeceutical product which utilizes the Company's Transdel(TM) technology. For more information, please visit http://www.transdelpharma.com.

Safe Harbor Statement

Statements made in this release that are not historical in nature constitute forward-looking statements. Forward-looking statements can be identified by the use of words such as "expects," "plans," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. P
'/>"/>

SOURCE Transdel Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Transdel Pharmaceuticals to Present at Cowen and Companys 28th Annual Health Care Conference
2. Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the Presidents Council on Physical Fitness and Sports, to Board of Directors
3. Transdel Expands Program to Include Cosmetic/Cosmeceutical Products
4. Transdel Pharmaceuticals, Inc. Retains FLP Pharma to Lead Business Development Activities
5. Transdel Pharmaceuticals, Inc. Featured on National Broadcast Television
6. Transdel Pharmaceuticals Enters Into License Agreement with JH Direct, LLC for Cosmeceutical Product
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals